9th Jul 2008 07:00
|
For Immediate Release |
9July 2008 |
ABCAM PLC
("Abcam" or "the Company")
Year-end Trading Update
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, is pleased to announce a trading update ahead of its results for the year ended 30 June 2008.
Following our positive trading update on 1 May 2008, the Company has continued to perform well and expects pre-tax profits for the year to modestly exceed expectations.
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
www.abcam.com
Numis Securities + 44 (0) 20 7776 1500
Nominated Adviser Michael Meade/ Nick Westlake
Corporate Broking James Black
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Mary-Jane Johnson / Susanna Gale
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of over 44,000 products, most of which are antibodies, from over 200 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs approximately 180 staff in its three operating companies.
Related Shares:
ABC.L